Physician profile
Kaylan Pustover
NPI 1871901918
$8,534.63
in general payments reported to CMS, 2019-2025
34 companies · $1,616 in 2025
The $1,616 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,278 · 2020: $815 · 2021: $1,220 · 2022: $1,106 · 2023: $1,361 · 2024: $1,139 · 2025: $1,616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,826 · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,826.15 |
| Education | $289.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,180.91 | 2020-2025 | |
| Galderma Laboratories, L.P. | $1,157.52 | 2019-2025 | Nemluvio, Dysport |
| Janssen Biotech, INC. | $1,013.61 | 2020-2025 | Tremfya, Simponi Aria, Simponi |
| Incyte Corporation | $773.75 | 2021-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $600.98 | 2019-2024 | Jublia, Cabtreo |
| Mayne Pharma Commercial LLC | $498.64 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $493.22 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $424.28 | 2019-2025 | Dupixent |
| Genzyme Corporation | $338.92 | 2020-2025 | |
| Lilly USA, LLC | $202.79 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $199.59 | 2022-2025 | Winlevi, Absorica Ld |
| Pfizer INC. | $185.57 | 2019-2025 | |
| Epi Health, LLC | $172.35 | 2020-2022 | |
| Vyne Pharmaceuticals INC. | $136.11 | 2020-2021 | |
| Leo Pharma INC. | $135.92 | 2021-2025 | Adbry, Anzupgo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $131.96 | 2022-2024 | Vtama |
| Amgen INC. | $104.88 | 2019-2025 | Otezla |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Botanix Sb INC | $82.08 | 2025 | Sofdra |
| Almirall LLC | $77.73 | 2019-2021 | |
| Ucb, INC. | $75.43 | 2022-2025 | Bimzelx |
| Allergan, INC. | $60.61 | 2021-2022 | |
| Dermira, INC. | $56.78 | 2019-2020 | |
| Journey Medical Corporation | $53.54 | 2020-2024 | |
| Arcutis Biotherapeutics, INC. | $51.76 | 2024-2025 | Zoryve |
| Celgene Corporation | $41.31 | 2019 | |
| Medimetriks Pharmaceuticals, INC. | $33.09 | 2019 | |
| Verrica Pharmaceuticals INC. | $32.30 | 2025 | Ycanth |
| Encore Dermatology INC. | $23.87 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.51 | 2025 | Sotyktu |
| Acelrx Pharmaceuticals, INC. | $22.91 | 2021 | |
| Aclaris Therapeutics, INC. | $20.36 | 2019 | |
| Mission Pharmacal Company | $14.30 | 2021 | |
| Prugen, INC. Pharmaceuticals | $14.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaylan Pustover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.